Highlights About two thirds of caregivers intend to vaccinate their children against COVID-19. Most common reason for acceptance was to protect the child. Most common reason for refusal was the vaccine’s novelty. Child age, chronic illness, vaccination history affects willingness. Caregiver gender, vaccination history, concern about infection affect willingness.
Purpose To determine predictors associated with caregivers’ willingness to accept an accelerated regulatory process for Coronavirus disease 2019 (COVID-19) vaccine development. Methods An international cross-sectional survey of 2557 caregivers arriving with their children to 17 pediatric Emergency Departments (ED) across six countries from March 26 to June 30, 2020. Caregivers were asked to select one of four choices they agreed with the most regarding a proposed COVID-19 vaccine approval process, in addition to questions regarding demographics, the ED visit, and attitudes about COVID-19. Univariate analyses were conducted using the Mann-Whitney test for comparing non-normal continuous variables, independent t-test for comparing normally distributed continuous variables, and Chi-square or Fisher’s exact test for categorical variables. Variables of interest subsequently underwent a multivariable logistic regression analysis to determine independent factors associated with caregivers’ willingness to accept abridged COVID-19 vaccine development. A p-value less than 0.05 was considered significant. Findings Almost half (1101/2557; 43%) of caregivers reported that they are willing to accept less rigorous testing and post-research approval for a new COVID-19 vaccine. Independent factors associated with willingness to expedite COVID-19 vaccine research included children that were up-to-date on their vaccination schedule (Odds Ratio (OR) = 1.72, 95% Confidence Interval (CI) = 1.29-2.31), caregivers concerned that they had COVID-19 at the time of survey completion in the ED (OR = 1.1, 95% CI 1.05-1.16), and caregivers that intend to vaccinate their children against COVID-19 if a vaccine becomes available (OR = 1.84, 95% CI 1.54-2.21). Mothers completing the survey were less likely to approve changes in the vaccine development process (OR = 0.64, 95% CI = 0.53-0.78). Implications Less than half of caregivers in a global sample are willing to accept abbreviated vaccine testing during the COVID-19 pandemic. As part of an effort to increase acceptance and uptake of the new vaccine, especially in order to protect children, public health strategies and individual providers should understand caregivers’ attitudes towards approval of the vaccine and consult them appropriately.
Question A child came to my clinic complaining of recurrent epistaxis with several episodes occurring every year since he was a toddler. The nosebleeds affect both nostrils, often lasting for an extended period of time and occurring in no apparent seasonal pattern. What interventions are safe and effective for recurrent epistaxis in children, and which patients warrant hematologic testing? Answer Epistaxis affects more than half of children by the time they are 10 years old, with 9% of children reported to have recurrent episodes. Most cases are of benign origin and will not require further workup. For those seeking intervention, nasal mucosal hydration, such as emollient application, or humidification resolves up to 65% of cases, and many novel interventions have shown promise in their respective initial studies. Standardized bleeding questionnaires have demonstrated usefulness in decision making for further coagulation studies, taking into account historical features including frequency, duration, bleeding site, seasonal correlation, and severity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.